Lord, Christopher J.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 6,683

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,185

BRCAness revisited

Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer

BRCA gene mutations in cancerPARP inhibition in cancer therapy

Cited by 1,257

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,011

A decade of clinical development of PARP inhibitors in perspective

Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 743

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications

Chromatin Remodeling and CancerDNA Repair Mechanisms

Cited by 382

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 373

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation

PARP inhibition in cancer therapyinterferon and immune responses

Cited by 332

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., & Ashworth, A. (2012) · EMBO Molecular Medicine

PARP inhibition in cancer therapySirtuins and Resveratrol in Medicine

Cited by 136

Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival

Tonnessen-Murray, C. A., Frey, W. D., Rao, S. G., Shahbandi, A., Ungerleider, N. A., Olayiwola, J. O., Murray, L. B., Vinson, B. T., Chrisey, D. B., Lord, C. J., et al. (2019) · Journal of Cell Biology

Telomeres, Telomerase, and SenescenceAutophagy in Disease and Therapy

Cited by 127

An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence.

Rovillain, E., Mansfield, L., Lord, C. J., Ashworth, A., & Jat, P. S. (2011) · BMC Genomics

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 43